1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD28

CD28

CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and provides a critical co-stimulatory signal. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. CD28 interacts with the CD80 dimer with relatively high affinity and the CD86 monomer with lower affinity, mediating T cell co-stimulation in conjunction with T cell receptor (TCR) signals. CD28 drives critical intracellular biochemical events including unique phosphorylation and transcriptional signaling, metabolism, and the production of key cytokines, chemokines, and survival signals that are essential for long-term expansion and differentiation of T cells. Most importantly, treatment of mice with a soluble CD28 antagonist induced antigen-specific tolerance that prevented the progression of autoimmune diseases and organ graft rejection.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9975
    Theralizumab
    Agonist 99.46%
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.
    Theralizumab
  • HY-P99302
    Lulizumab
    Inhibitor
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling.
    Lulizumab
  • HY-P99123
    Anti-Mouse CD28 Antibody (37.51)
    Anti-Mouse CD28 Antibody is an anti-mouse CD28 IgG antibody inhibitor derived from the host Syrian Hamster.
    Anti-Mouse CD28 Antibody (37.51)
  • HY-102090
    B7/CD28 interaction inhibitor 1
    99.47%
    B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM.
    B7/CD28 interaction inhibitor 1
  • HY-P99961
    Tifcemalimab
    Inhibitor
    Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer.
    Tifcemalimab
  • HY-P990773
    Venanprubart
    Inhibitor 98.00%
    Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Venanprubart
  • HY-P991038
    Zadoprubart
    HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Zadoprubart
  • HY-P990938
    Pegrizeprument
    HY-P990938 is an CD28-targeting Fab'-G1 -κ type chimeric antibody.
    Pegrizeprument
  • HY-P99414
    Prezalumab
    Inhibitor 99.23%
    Prezalumab (AMG 557) is a monoclonal antibody targeting ICOSL that has synergistic anti-inflammatory activity with CD28 antibody inhibitors.
    Prezalumab
  • HY-P99420
    Acazicolcept
    Antagonist 99.27%
    Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities.
    Acazicolcept
  • HY-P99293
    Galiximab
    Inhibitor 99.23%
    Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma.
    Galiximab
  • HY-P1698
    Reltecimod
    Antagonist 99.88%
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).
    Reltecimod
  • HY-P1698B
    Reltecimod TFA
    Chemical 99.78%
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs).
    Reltecimod TFA
  • HY-100891
    CD80-IN-3
    98.08%
    CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC50 of 630 nM and a Kd of 125 nM.
    CD80-IN-3
  • HY-P990236
    Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A)
    Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse/rat/monkey/human ICOS/CD278.
    Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A)
  • HY-P990819
    Anti-Rat CD28 Antibody (JJ316)
    Inhibitor
    Anti-Rat CD28 Antibody (JJ316) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Rat CD28 Antibody (JJ316): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-Rat CD28 Antibody (JJ316)
  • HY-P99431
    KY-1044
    99.51%
    KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response.
    KY-1044
  • HY-P990752
    Nezastomig
    Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Nezastomig
  • HY-P990793
    Anti-Mouse CD28 Antibody (D665)
    Inhibitor
    Anti-Mouse CD28 Antibody (D665) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Mouse CD28 Antibody (D665): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-Mouse CD28 Antibody (D665)
  • HY-N10445
    Maydispenoid A
    Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation.
    Maydispenoid A
Cat. No. Product Name / Synonyms Application Reactivity